Engineering a Brighter Future: The Evolving Role of the Pharmacist in the Era of the HeartMate 3
Keyword(s):
Continuous-flow left-ventricular assist devices (CF-LVADs) are an option for patients with end-stage heart failure requiring durable mechanical circulatory support. Two of the older-generation CF-LVADs have been associated with multiple device-related complications, including bleeding and thrombosis. The newest generation CF-LVAD, the HeartMate 3, was engineered specifically to prevent device-related thrombosis. As more data enhance our understanding of the burden of bleeding and thrombotic adverse events, patients with durable mechanical circulatory support may require less-aggressive antithrombotic therapy.
2017 ◽
Vol 36
(4)
◽
pp. S101
2019 ◽
Vol 38
(4)
◽
pp. S230-S231
2008 ◽
Vol 27
(2)
◽
pp. S197
2020 ◽
Vol 31
(4)
◽
pp. 475-482
2018 ◽
Vol 32
(3)
◽
pp. 1193-1213
◽
2016 ◽
Vol 48
(5)
◽
pp. 1770-1774
2016 ◽
Vol 35
(4)
◽
pp. S265-S266